Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 225ac Radioisotope
2. Ac-225 Radioisotope
1. 14265-85-1
2. E95cp8xct3
3. Actinium, Isotope Of Mass 225 (225ac3+)
4. 1261243-53-1
5. Actinium, Isotope Of Mass 225
6. Actinium Ac-225
7. (~225~ac)actinium
8. Actinium Cation Ac-225
9. Unii-e95cp8xct3
10. Hi04acm8i1
11. Actinium +3 Cation Ac-225
12. Dtxsid50931577
| Molecular Weight | 225.02323 g/mol |
|---|---|
| Molecular Formula | Ac |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Exact Mass | 225.02323 g/mol |
| Monoisotopic Mass | 225.02323 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 1 |
| Formal Charge | 0 |
| Complexity | 0 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38736
Submission : 2023-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34308
Submission : 2019-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35378
Submission : 2020-12-23
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38736
Submission : 2023-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35378
Submission : 2020-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34308
Submission : 2019-12-20
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of large cell neuroendocrine carcinoma.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Gets FDA Orphan Drug Designation For ABD-147 in Neuroendocrine Carcinoma
Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of large cell neuroendocrine carcinoma.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 05, 2024
Details:
ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Therapeutics Gets FDA Fast Track Designation for ABD-147 in Small Cell Lung Cancer
Details : ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 27, 2024
Details:
ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 23, 2024
Details:
Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Fusion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 16, 2023
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2023
Details:
The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and extensive-stage SCLC.
Lead Product(s): RYZ801,Actinium-225
Therapeutic Area: Oncology Brand Name: RYZ801
Study Phase: IND EnablingProduct Type: Peptide
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2023
Lead Product(s) : RYZ801,Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
RayzeBio Announces Initial Public Offering
Details : The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and exte...
Brand Name : RYZ801
Molecule Type : Peptide
Upfront Cash : Undisclosed
August 25, 2023
Details:
The collaboration aims to evaluate radiopharmaceutical versions of MNPR-101 RIT in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).
Lead Product(s): MNPR-101,Actinium-225
Therapeutic Area: Oncology Brand Name: MNPR-101 RIT
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Cancer Science Institute of Singapore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2023
Lead Product(s) : MNPR-101,Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Cancer Science Institute of Singapore
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to evaluate radiopharmaceutical versions of MNPR-101 RIT in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).
Brand Name : MNPR-101 RIT
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 11, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: RYZ101
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.
Brand Name : RYZ101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Details:
Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal healthy tissue.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Yonghe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 27, 2022
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Yonghe Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Actinium-225 is an alpha emitting radioactive particle that has high energy density acting at distances of just a few cell widths. At these short distances, radiation can be restricted to the cancer cells of interest with minimal risk to nearby normal he...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 27, 2022
Details:
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: PNT2001
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225.
Brand Name : PNT2001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 17, 2022
Details:
Proceeds from the financing will be used by Ablaze to establish a leading pipeline of advanced TRT products having Actinium-225 for the treatment of solid tumors, build up infrastructure for radiopharmaceuticals and secure further strategic collaborations.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Vivo Capital
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 29, 2021
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Vivo Capital
Deal Size : $75.0 million
Deal Type : Series A Financing
Details : Proceeds from the financing will be used by Ablaze to establish a leading pipeline of advanced TRT products having Actinium-225 for the treatment of solid tumors, build up infrastructure for radiopharmaceuticals and secure further strategic collaboration...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
18 Oct 2024
// BUSINESSWIRE
01 Oct 2024
// BUSINESSWIRE
22 Jul 2024
// BUSINESSWIRE
07 Jun 2024
// BUSINESSWIRE
07 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ionetix-produces-first-batch-of-actinium-255-302167033.html
08 Jan 2024
// BUSINESSWIRE
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Share 
